Chronic Kidney Disease Market Summary
As per Market Research Future Analysis, the Global Chronic Kidney Disease Market was valued at USD 40.53 Billion in 2024 and is projected to grow from USD 40.53 Billion in 2024 to USD 75.22 Billion by 2035, with a CAGR of 5.78% during the forecast period. The market growth is driven by the increasing prevalence of kidney diseases, rising biopsy procedures, and demand for advanced diagnostic techniques. Notable developments include AWAK Technologies raising over $20 million for innovative dialysis solutions and the formation of Mozarc Medical by Medtronic and DaVita to enhance renal care technologies. The market is characterized by significant R&D activities and favorable reimbursement policies, particularly in emerging markets.
Key Market Trends & Highlights
Key trends driving the Chronic Kidney Disease market include increasing disease prevalence and technological advancements.
- Chronic Kidney Disease affects 10% of the global population, highlighting a significant health concern.
- The blood tests segment is expected to dominate the market due to rising CKD burdens and advanced diagnostic products.
- North America is projected to be the fastest-growing market, driven by high healthcare spending and advanced diagnostic technologies.
- The Type 1 or Type 2 diabetes segment is anticipated to hold the majority share due to the rising prevalence of diabetes.
Market Size & Forecast
2024 Market Size | USD 40.53 Billion |
2035 Market Size | USD 75.22 Billion |
CAGR (2024-2035) | 5.78% |
Major Players
Key players include Abbott (US), Siemens (Germany), Beckman Coulter (US), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca (UK), and GlaxoSmithKline Plc (UK).